Cost-Effectiveness Analysis of Percutaneous Sclerotherapy for Venous Malformations

Yusuke Ono, Keigo Osuga, Tomoyuki Takura, Masahisa Nakamura, Kentaro Shibamoto, Akira Yamamoto, Hiroyasu Fujiwara, Hidefumi Mimura, Noriyuki Tomiyama

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Purpose: To assess cost-effectiveness of sclerotherapy for venous malformations (VMs) to improve patient quality of life (QOL). Materials and Methods: This prospective study enrolled 28 patients with symptomatic VMs who underwent sclerotherapy. EuroQol-5 Dimension (EQ-5D) and Short-Form 36 (SF-36) Health Survey were used to measure health-related QOL. Questionnaires were collected before and 1, 3, 6, and 12 months after sclerotherapy. Quality-adjusted life years (QALYs) were calculated using EQ-5D score as a measure of health utility. Medical costs obtained from the hospital accounting system and other costs of staff, drugs, materials, and angiographic equipment were calculated for each procedure. Cost-effectiveness was analyzed using incremental cost-effectiveness ratio (ICER) as the medical cost/gain of QALYs. Results: Median EQ-5D scores improved from 0.768 (range, 0.705-1) to 1 (range, 0.768-1) after 6 months (P = .023) and 1 (range, 0.768-1) after 12 months (P = .063). The gain of QALYs at 12 months was 0.043. The mean medical cost was ¥281,228 ($2,337). The pain group (baseline bodily pain scale of SF-36 score <70) showed greater improvement in median EQ-5D score, from 0.705 (range, 0.661-0.768) to 0.768 (range, 0.705-1) after 6 months (P = .041) and 0.768 (range, 0.768-1) after 12 months (P = .049). ICER at 12 months was ¥6,600,483 ($54,840) in the overall group and decreased to ¥3,998,113 ($33,218) in the pain group, <¥6,000,000 ($49,850), threshold for acceptance of a public health benefit in Japan, even accounting for 50% increase in costs. Conclusions: Sclerotherapy was cost-effective for improving QOL for symptomatic VMs, especially for patients with moderate to severe pain.

Original languageEnglish
JournalJournal of Vascular and Interventional Radiology
DOIs
Publication statusAccepted/In press - Sep 4 2015

Fingerprint

Sclerotherapy
Cost-Benefit Analysis
Quality-Adjusted Life Years
Costs and Cost Analysis
Pain
Quality of Life
Drug Costs
Hospital Costs
Insurance Benefits
Health Surveys
Japan
Public Health
Prospective Studies
Equipment and Supplies
Health

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

Ono, Y., Osuga, K., Takura, T., Nakamura, M., Shibamoto, K., Yamamoto, A., ... Tomiyama, N. (Accepted/In press). Cost-Effectiveness Analysis of Percutaneous Sclerotherapy for Venous Malformations. Journal of Vascular and Interventional Radiology. https://doi.org/10.1016/j.jvir.2015.12.019

Cost-Effectiveness Analysis of Percutaneous Sclerotherapy for Venous Malformations. / Ono, Yusuke; Osuga, Keigo; Takura, Tomoyuki; Nakamura, Masahisa; Shibamoto, Kentaro; Yamamoto, Akira; Fujiwara, Hiroyasu; Mimura, Hidefumi; Tomiyama, Noriyuki.

In: Journal of Vascular and Interventional Radiology, 04.09.2015.

Research output: Contribution to journalArticle

Ono, Y, Osuga, K, Takura, T, Nakamura, M, Shibamoto, K, Yamamoto, A, Fujiwara, H, Mimura, H & Tomiyama, N 2015, 'Cost-Effectiveness Analysis of Percutaneous Sclerotherapy for Venous Malformations', Journal of Vascular and Interventional Radiology. https://doi.org/10.1016/j.jvir.2015.12.019
Ono, Yusuke ; Osuga, Keigo ; Takura, Tomoyuki ; Nakamura, Masahisa ; Shibamoto, Kentaro ; Yamamoto, Akira ; Fujiwara, Hiroyasu ; Mimura, Hidefumi ; Tomiyama, Noriyuki. / Cost-Effectiveness Analysis of Percutaneous Sclerotherapy for Venous Malformations. In: Journal of Vascular and Interventional Radiology. 2015.
@article{dfa6758d0d604bcd947a9eb5055d37b1,
title = "Cost-Effectiveness Analysis of Percutaneous Sclerotherapy for Venous Malformations",
abstract = "Purpose: To assess cost-effectiveness of sclerotherapy for venous malformations (VMs) to improve patient quality of life (QOL). Materials and Methods: This prospective study enrolled 28 patients with symptomatic VMs who underwent sclerotherapy. EuroQol-5 Dimension (EQ-5D) and Short-Form 36 (SF-36) Health Survey were used to measure health-related QOL. Questionnaires were collected before and 1, 3, 6, and 12 months after sclerotherapy. Quality-adjusted life years (QALYs) were calculated using EQ-5D score as a measure of health utility. Medical costs obtained from the hospital accounting system and other costs of staff, drugs, materials, and angiographic equipment were calculated for each procedure. Cost-effectiveness was analyzed using incremental cost-effectiveness ratio (ICER) as the medical cost/gain of QALYs. Results: Median EQ-5D scores improved from 0.768 (range, 0.705-1) to 1 (range, 0.768-1) after 6 months (P = .023) and 1 (range, 0.768-1) after 12 months (P = .063). The gain of QALYs at 12 months was 0.043. The mean medical cost was ¥281,228 ($2,337). The pain group (baseline bodily pain scale of SF-36 score <70) showed greater improvement in median EQ-5D score, from 0.705 (range, 0.661-0.768) to 0.768 (range, 0.705-1) after 6 months (P = .041) and 0.768 (range, 0.768-1) after 12 months (P = .049). ICER at 12 months was ¥6,600,483 ($54,840) in the overall group and decreased to ¥3,998,113 ($33,218) in the pain group, <¥6,000,000 ($49,850), threshold for acceptance of a public health benefit in Japan, even accounting for 50{\%} increase in costs. Conclusions: Sclerotherapy was cost-effective for improving QOL for symptomatic VMs, especially for patients with moderate to severe pain.",
author = "Yusuke Ono and Keigo Osuga and Tomoyuki Takura and Masahisa Nakamura and Kentaro Shibamoto and Akira Yamamoto and Hiroyasu Fujiwara and Hidefumi Mimura and Noriyuki Tomiyama",
year = "2015",
month = "9",
day = "4",
doi = "10.1016/j.jvir.2015.12.019",
language = "English",
journal = "Journal of Vascular and Interventional Radiology",
issn = "1051-0443",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Cost-Effectiveness Analysis of Percutaneous Sclerotherapy for Venous Malformations

AU - Ono, Yusuke

AU - Osuga, Keigo

AU - Takura, Tomoyuki

AU - Nakamura, Masahisa

AU - Shibamoto, Kentaro

AU - Yamamoto, Akira

AU - Fujiwara, Hiroyasu

AU - Mimura, Hidefumi

AU - Tomiyama, Noriyuki

PY - 2015/9/4

Y1 - 2015/9/4

N2 - Purpose: To assess cost-effectiveness of sclerotherapy for venous malformations (VMs) to improve patient quality of life (QOL). Materials and Methods: This prospective study enrolled 28 patients with symptomatic VMs who underwent sclerotherapy. EuroQol-5 Dimension (EQ-5D) and Short-Form 36 (SF-36) Health Survey were used to measure health-related QOL. Questionnaires were collected before and 1, 3, 6, and 12 months after sclerotherapy. Quality-adjusted life years (QALYs) were calculated using EQ-5D score as a measure of health utility. Medical costs obtained from the hospital accounting system and other costs of staff, drugs, materials, and angiographic equipment were calculated for each procedure. Cost-effectiveness was analyzed using incremental cost-effectiveness ratio (ICER) as the medical cost/gain of QALYs. Results: Median EQ-5D scores improved from 0.768 (range, 0.705-1) to 1 (range, 0.768-1) after 6 months (P = .023) and 1 (range, 0.768-1) after 12 months (P = .063). The gain of QALYs at 12 months was 0.043. The mean medical cost was ¥281,228 ($2,337). The pain group (baseline bodily pain scale of SF-36 score <70) showed greater improvement in median EQ-5D score, from 0.705 (range, 0.661-0.768) to 0.768 (range, 0.705-1) after 6 months (P = .041) and 0.768 (range, 0.768-1) after 12 months (P = .049). ICER at 12 months was ¥6,600,483 ($54,840) in the overall group and decreased to ¥3,998,113 ($33,218) in the pain group, <¥6,000,000 ($49,850), threshold for acceptance of a public health benefit in Japan, even accounting for 50% increase in costs. Conclusions: Sclerotherapy was cost-effective for improving QOL for symptomatic VMs, especially for patients with moderate to severe pain.

AB - Purpose: To assess cost-effectiveness of sclerotherapy for venous malformations (VMs) to improve patient quality of life (QOL). Materials and Methods: This prospective study enrolled 28 patients with symptomatic VMs who underwent sclerotherapy. EuroQol-5 Dimension (EQ-5D) and Short-Form 36 (SF-36) Health Survey were used to measure health-related QOL. Questionnaires were collected before and 1, 3, 6, and 12 months after sclerotherapy. Quality-adjusted life years (QALYs) were calculated using EQ-5D score as a measure of health utility. Medical costs obtained from the hospital accounting system and other costs of staff, drugs, materials, and angiographic equipment were calculated for each procedure. Cost-effectiveness was analyzed using incremental cost-effectiveness ratio (ICER) as the medical cost/gain of QALYs. Results: Median EQ-5D scores improved from 0.768 (range, 0.705-1) to 1 (range, 0.768-1) after 6 months (P = .023) and 1 (range, 0.768-1) after 12 months (P = .063). The gain of QALYs at 12 months was 0.043. The mean medical cost was ¥281,228 ($2,337). The pain group (baseline bodily pain scale of SF-36 score <70) showed greater improvement in median EQ-5D score, from 0.705 (range, 0.661-0.768) to 0.768 (range, 0.705-1) after 6 months (P = .041) and 0.768 (range, 0.768-1) after 12 months (P = .049). ICER at 12 months was ¥6,600,483 ($54,840) in the overall group and decreased to ¥3,998,113 ($33,218) in the pain group, <¥6,000,000 ($49,850), threshold for acceptance of a public health benefit in Japan, even accounting for 50% increase in costs. Conclusions: Sclerotherapy was cost-effective for improving QOL for symptomatic VMs, especially for patients with moderate to severe pain.

UR - http://www.scopus.com/inward/record.url?scp=84959874589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959874589&partnerID=8YFLogxK

U2 - 10.1016/j.jvir.2015.12.019

DO - 10.1016/j.jvir.2015.12.019

M3 - Article

C2 - 26972615

AN - SCOPUS:84959874589

JO - Journal of Vascular and Interventional Radiology

JF - Journal of Vascular and Interventional Radiology

SN - 1051-0443

ER -